Akebia Therapeutics, Inc. (AKBA) stock rallied over 10.51% intraday to trade at $0.39 a share on NASDAQ. The stock opened with a gain of 16.42% at $0.355 and touched an intraday high of $0.396, rising 9.55% against the last close of $0.356. The stock went to a low of $0.351 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue213.58 Million
5Y Sales Change168.30%
Fiscal Year Ends2021-12-30
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Akebia Therapeutics, Inc. (NASDAQ: AKBA) stock price is $0.39 as of the last check on Thursday, June 23. During the trading session, AKBA stock reached the peak price of $0.396 while $0.351 was the lowest point it dropped to.
The NASDAQ listed AKBA is part of Biotechnology industry that operates in the broader Health Care sector. Akebia Therapeutics, Inc. , a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
Mr. Jason A. Amello
Mr. John P. Butler MBA
CEO, Pres & Director
Mr. David A. Spellman
Sr. VP, CFO & Treasurer
Mr. Michel Dahan
Sr. VP & COO
AKBA stock traded closed the last session at $0.393, which is $0.03 or 10.51% lower than its previous close of $0.356. AKBA's current trading price is 31.07% lower than its 52-week high of $4.33 where as its distance from 52-week low of 0.30% is -90.92%.
Number of AKBA employees currently stands at -. AKBA operates from 245 First Street, Suite 1400, Cambridge, MA 02142, United States.
Official Webiste of $AKBA is: https://www.akebia.com
AKBA stock volume for the day was 7,815,940 shares while in the previous session number of AKBA shares traded was 7,831,600 . The average number of AKBA shares traded daily for last 3 months was 12.48 Million.
The percentage change in AKBA stock occurred in the recent session was 10.51% while the dollar amount for the price change in AKBA stock was $0.03.
In the recent session, the day high for AKBA stock was $0.396 while the low for AKBA stock touched on the day was $0.351.
The market value of AKBA currently stands at 67.72 Million with its latest stock price at $0.39 and 179.6 Million of its shares outstanding.